The Pharma Data

DECEMBER 31, 2020

31, 2020 — Blood vessel damage and inflammation in the brains of deceased COVID-19 patients suggest the damage is not caused by the virus, but the body’s immune response to it. The spots were surrounded by T cells — signs of an immune response. © 2020 HealthDay. Posted: December 2020.

Immune Response 52

Immune Response Virus Doctors Research 52

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Replimune Group, Inc. The offering is expected to close on October 26, 2020, subject to the satisfaction of customary closing conditions. headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immuno-gene therapies for the treatment of cancer. BOSTON, Oct.

Immune Response 40

Immune Response Clinical Trials Production Therapies 40

Drug Target Review

JANUARY 15, 2024

The pathogenesis of COPD is based on the innate and adaptive inflammatory immune response to the inhalation of toxic particles and gases. 1 Lung transplantation is the only viable treatment option, yet finding suitable lung donors is difficult. 2020 October 1 [2024 January 5]; 27(4):523-31. Cell Stem Cell.

Immune Response 113

Immune Response Disease Science Therapies 113

The Pharma Data

OCTOBER 27, 2020

27, 2020 /PRNewswire/ — Mirati Therapeutics, Inc. The offering is expected to close on or about October 30, 2020 , subject to customary closing conditions. SAN DIEGO , Oct. Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

The Pharma Data

DECEMBER 13, 2020

14, 2020 /PRNewswire/ — Synlogic, Inc. SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response.

Immune Response 40

Immune Response Treatment Engineering Clinical Trials 40

Drug Discovery World

APRIL 20, 2023

There is a clear opportunity to repurpose some of these candidates for preventative/ prophylactic treatment for post-Covid-19 cognitive impairment. These may provide an opportunity for treatment for post-Covid-19 cognitive impairment. New therapeutics of course depend on an understanding of biological mechanisms.

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

NIH Director's Blog: Drug Development

JUNE 30, 2020

But there is a catch: 99 percent of the study’s participants didn’t make enough neutralizing antibodies to mount an ideal immune response. That brings more reason for hope that the many vaccines now under study to elicit such neutralizing antibodies in sufficient numbers may afford us with much-needed immune protection.

Immune Response 52

Immune Response Virus Vaccine Research 52

The Pharma Data

DECEMBER 18, 2020

18, 2020 — Allergic reactions to vaccines are generally rare and people with common allergies are not more likely to have a reaction to the Pfizer-BioNTech COVID-19 vaccine, according to guidance released by the American College of Allergy, Asthma & Immunology (ACAAI). © 2020 HealthDay. Posted: December 2020.

Vaccine 52

Vaccine Immune Response Treatment Drugs 52

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. Sanofi and GSK’s adjuvanted recombinant protein-based COVID-19 vaccine candidate was selected in July 2020 by the U.S. In parallel, development work on new SARS-CoV-2 variants underway.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

MAY 6, 2021

This donation of the vaccine is another tool in our toolbox of measures to help make the Olympic and Paralympic Games Tokyo 2020 safe and secure for all participants and to show solidarity with our gracious Japanese hosts,” said IOC President Thomas Bach. “We This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications. Nature 578 , 229-236 (2020). References Doudna JA.

Engineering 105

Engineering Virus Therapies Immune Response 105

The Pharma Data

SEPTEMBER 8, 2021

While these results are disappointing, w e believe th e rilzabrutinib clinical program holds great potential to address the unmet treatment needs of people living with immune-mediated diseases , ” said Naimish Patel, Head of Global Development, Immunology and Inflammation. “ 2020 Apr 9;72(9):1435–46. doi: 10.1002/art.41275.

Immune Response 52

Immune Response Trials Treatment Disease 52

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. © 2020 HealthDay. Posted: December 2020. TUESDAY, Dec. Source link.

Vaccine 52

Vaccine Immune Response Treatment Disease 52

The Pharma Data

OCTOBER 16, 2020

12 to 16, 2020. 16, 2020 — A case of reinfection with severe acute respiratory syndrome coronavirus 2 is described in a study published online Oct. COVID-19 Antibody Treatment Study Paused. Immune Responses Long-Lasting After Serious COVID-19. Reinfection With SARS-CoV-2 Described in 25-Year-Old. FRIDAY, Oct.

Hospitals 52

Hospitals Immune Response Vaccine Trials 52

The Pharma Data

NOVEMBER 22, 2020

23, 2020 10:10 UTC. The TALON effector modules are based on immunomodulatory molecules that act as regulatory control points within the immune system. In conjunction with a tissue-specific targeting moiety, the effectors create novel bifunctional molecules for the treatment of autoimmune and inflammatory diseases.

Immune Response 52

Immune Response Engineering Clinical Research Disease 52

The Pharma Data

NOVEMBER 9, 2020

10, 2020 06:00 UTC. Additionally, the vast majority of patients only receive a temporary benefit or no benefit from ICIs, as they either develop resistance to the treatment during the course of therapy or are non-responsive to the treatment altogether (only 15%-20% of patients respond, according to published data).

Immune Response 40

Immune Response Therapies Clinical Trials Treatment 40

The Pharma Data

NOVEMBER 12, 2020

12, 2020 — Lung cancer patients who harbor certain bacteria in the airways may have a poorer prognosis, a new study finds, adding to evidence that the body’s “microbiome” may play a role in cancer patients’ outlook. © 2020 HealthDay. Posted: November 2020. THURSDAY, Nov. All rights reserved.

Immune Response 52

Immune Response Doctors Research Treatment 52

NIH Director's Blog: Drug Development

MARCH 18, 2021

Now, Veesler and his lab are turning to another mammal in their search for new leads for the next generation of antiviral treatments, including ones aimed at the coronavirus that causes COVID-19, SARS-CoV-2. With support from a 2020 NIH Director’s Pioneer Award, Veesler will study members of the order Chiroptera.

Virus 52

Virus Immune Response Clinical Trials Vaccine 52

The Pharma Data

NOVEMBER 12, 2020

12 November 2020 — The CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised with respiratory symptoms of COVID-19 did not meet the primary efficacy endpoint. Accessed October 2020. Accessed October 2020. Posted: November 2020. NCT identifier: NCT04380688. Available online.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The agreement was first expanded in March 2020 to include development of a novel mRNA vaccine for COVID-19. Expected to enroll 415 participants; interim results expected in Q3 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

APRIL 22, 2023

The Atlas of MS reported in 2020 that someone is diagnosed with MS every five minutes around the world, adding to about 2.8 When infused back into a mouse model of MS, the backpack-laden monocytes were able to affect MS-specific immune responses, and partially reverse hind limb paralysis and improve motor functions.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

The Pharma Data

DECEMBER 23, 2020

24, 2020 07:00 UTC. TREM-1 is an immunomodulatory receptor expressed on innate immune and endothelial cells which amplifies and maintains inflammation. Based upon an interim analysis, an independent DMC recommended on December 21, 2020 the continuation of Inotrem’s Phase IIa clinical trial for which results are expected early Q2 2021.

Clinical Trials 52

Clinical Trials Trials Research Immune Response 52

The Pharma Data

DECEMBER 28, 2020

29, 2020 /PRNewswire/ — Moleculin Biotech , Inc., 29, 2020 /PRNewswire/ — Moleculin Biotech , Inc., Taken together, these factors suggest that Annamycin could represent an important treatment to help address a significant unmet need in patients with STS lung metastases. . .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

JANUARY 3, 2021

Anecdotal feedback from Foralumab-treated patients was positive and suggests that the treatment was well-tolerated. This trial is the first to evaluate nasally administered Foralumab to improve the immune system’s fight against coronaviruses. NEW YORK and LONDON, Jan.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

DECEMBER 10, 2020

11, 2020 02:48 UTC. The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

DECEMBER 22, 2020

22, 2020 — For Americans who are worried about the new coronavirus variant that is circulating in Britain, experts in the United States urge everyone to stay calm. ” How common are variants of viruses and do they generally impact effectiveness of vaccines or treatments? ” © 2020 HealthDay. TUESDAY, Dec.

Virus 52

Virus Vaccine Immune Response Treatment 52

The Pharma Data

NOVEMBER 9, 2020

10, 2020 (GLOBE NEWSWIRE) — Immunophotonics, Inc. Coordinating Investigator of the trial commented, “IP-001 combines the promise of modern immunotherapy with the trend towards intratumoral treatment. SAKK is excited to bring this novel treatment to patients in desperate need for new innovative treatment options.”.

Clinical Trials 40

Clinical Trials Immune Response Trials Clinical Development 40

PLOS: DNA Science

JANUARY 4, 2024

They shared the Nobel Prize in Chemistry in 2020. The microbes deploy them to dismantle the genetic material of infecting viruses, a little like an immune response. Sickle Cell Disease The CRISPR-based treatment for sickle cell disease is Casgevy , from CRISPR Therapeutics and Vertex Pharmaceuticals. Perhaps one of these.

FDA Approval 52

FDA Approval DNA Clinical Trials Therapies 52

Drug Discovery World

JULY 22, 2022

Although immunotherapy has revolutionised cancer therapy, the effectiveness of currently available immunotherapies varies significantly across patients and treatment types. As a result, researchers are striving to continually improve immuno-oncology approaches using the patient’s own immune cells to combat tumours.

Therapies 130

Therapies Treatment Engineering Clinical Trials 130

The Pharma Data

DECEMBER 9, 2020

9, 2020 — COVID-19 can cause a wide range of neurological complications, even in patients who are not critically ill, a new study shows. The patient improved after treatment with anti-inflammatory corticosteroids. ” © 2020 HealthDay. Posted: December 2020. WEDNESDAY, Dec. All rights reserved. Source link.

Hospitals 52

Hospitals Doctors Immune Response Nurses 52

NIH Director's Blog: Drug Development

MAY 21, 2020

Science, 2020 We now know that the immune system of nearly everyone who recovers from COVID-19 produces antibodies against SARS-CoV-2, the novel coronavirus that causes this easily transmitted respiratory disease [1]. Preprint Posted May 5, 2020. [2] Preprint Posted May 5, 2020. [2] 2020 May 18.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. . PLYMOUTH MEETING, Pa. , Only 6 related Grade 1 adverse events in 5 subjects were observed, primarily mild injection site reactions (e.g.,

DNA 40

DNA Vaccine Immune Response Clinical Trials 40

Drug Discovery World

SEPTEMBER 6, 2022

billion in 2020, according to the Alliance for Regenerative Medicine’s (ARM’s) Regenerative Medicine: Disrupting the Status Quo report. And whilst clinical trials activity decreased by around 15% compared to 2020, last year still saw a number of regenerative medicines reach the bedside. billion, compared to $19.9

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Adicet Bio, Inc. T cell therapy expressing a chimeric antigen receptor (CAR) targeting CD20 for treatment of non-Hodgkin’s lymphoma (NHL). ADI-001 is an investigational allogeneic gamma delta T cell therapy being developed as a treatment for B-cell non-Hodgkin’s lymphoma (NHL). and BOSTON, Oct.

FDA 40

FDA Immune Response Engineering Clinical Trials 40

The Pharma Data

SEPTEMBER 17, 2020

Basel, 18 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its Elecsys® Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark. 1,5 All candidate vaccines in Phase III or approved for limited / early use aim to induce an antibody response against the SARS-CoV-2 spike protein.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

The Pharma Data

NOVEMBER 19, 2020

As of November 15, 2020, according to the U.S. The study not only confirms treatment should start early, but suggests that treatment should focus on addressing the causes of this far earlier trigger. Census Bureau and compared the provisional non-COVID-19 death numbers for 2020. with at least 799 recorded deaths.

Research 52

Research Nurses Disease Immune Response 52

Broad Institute

OCTOBER 4, 2023

This is an unprecedented opportunity to evaluate how immune responses work,” said Robert Manguso , who is co-senior author on the study, an associate member at the Broad, and an assistant professor at the Massachusetts General Hospital Center for Cancer Research and Harvard Medical School.

Small Molecule 128

Small Molecule Clinical Trials Engineering Medical Schools 128